| NCT02693535 | II | Ovarian expansion for CDKN2A loss or mutation or ERBB2/ERBB3 amplification, mutation or over-expression, or high TMB or Advanced solid tumors with molecular alterations in AKT1, ATM, ATR, BRAF, BRCA1/2, CDK4/6 AMP, CDK12, CDKN2A, CDKN2B, CHEK2, CSF1R, FANCA, FGFR1/2/3/4, FLT3, KIT, MRE11A, MLH1, MSH2, MSH6, NBN, NTRK1/2/3 AMP, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RAD51C, RET, TSC1/2, VEGFR, or with high MSI, high TMB, HRD+, or LOHhi | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | AL, AZ, CA, CT, FL, GA, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WI | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Futibatinib | TAS-120, FGFR inhibitor TAS-120 | FGFR1-4 inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Larotrectinib | Trk inhibitor LOXO-101, LOXO-101, Vitrakvi | pan-Trk kinase inhibitor | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | PHESGO | pertuzumab, trastuzumab, and hyaluronidase-zzxf | HER2 antagonist | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Temsirolimus | Torisel, CCI-779 | mTOR inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT02628067 | II | Advanced solid tumors with high MSI or high TMB | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | CA, MA, NJ | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02675829 | II | Advanced solid tumors with HER2 amplification | A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | NJ, NY | View Drugs | View Results |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT03212274 | II | Advanced solid tumors with IDH1 or IDH2 mutations | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | CA, FL, KS, MD, MA, MO, NH, NC, OH, OK, PA, TN, TX, UT, WI | View Drugs | |
|
|
| NCT03310879 | II | Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications | A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | MA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03412877 | II | Advanced solid tumors | A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer | MD | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Individual Patient TCR-Transduced PBL | autologous PBLs retrovirally-transduced with TCRs targeting neoantigens | Immune response against neoantigens | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03428802 | II | Advanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ, NY | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03579316 | II | Platinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitor | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | MA, TX | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A or ATM alterations | Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03742895 | II | Advanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+ | A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | MD, NJ, NY, WA | View Drugs | View Results |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | OK, WA | View Drugs | View Results |
Stenoparib | PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121 | PARP inhibitor | Clinical Trials |
|
|
| NCT01174121 | II | Advanced solid tumors | A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab | MD | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Selected Young TIL | | Immune response against tumor-associated antigens | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | CAPE, Xeloda | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03935893 | II | Advanced solid tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers | PA | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Autologous TILs | | Immune response against tumor-associated antigens | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT02710253 | II | Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Adagrasib | KRAS G12C inhibitor MRTX849, MRTX849 | KRAS G12C inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | GDC-0084, PI3K inhibitor GDC-0084, RG7666 | PI3K/mTOR inhibitor | Clinical Trials |
|
|
| NCT04055649 | II | Platinum resistant or refractory ovarian cancer (at most 4 prior therapies for platinum resistant disease) | Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | MI | View Drugs | View Results |
ONC201 | AKT/ERK inhibitor ONC201, TIC10 | AKT and ERK kinase inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04198766 | II | Advanced solid tumors with dMMR, high MSI or high TMB | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | CA, GA, IL, IA, KY, MI, NE, OR, TN, TX, VA, WI | View Drugs | View Results |
INBRX-106 | INBRX-106: Hexavalent OX40 Agonist | Stimulates OX40 to increase T cell activation and immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04339140 | II | Recurrent ovarian cancer (only detectable by rising CA125) | A Phase 2 Study of Zafirlukast for the Treatment of Tumor-marker Only Relapsed Ovarian Cancer | MA | View Drugs | |
Zafirlukast | Accolate | CYSLTR1 antagonist | Approved in Other Indications |
|
|
| NCT04387227 | II | Recurrent ovarian cancer (only detectable by rising CA125) | A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer | WA | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04534283 | II | Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1 | A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1. | IN | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Temuterkib | LY3214996 | ERK inhibitor | Clinical Trials |
|
|
| NCT04550494 | II | Advanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | FL, MD, OK | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | MI, TX, UT, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in ALK, ATM, BRAF (class III), KRAS G12C, NTRK1/2/3, PIK3CA (multiple mutations), RET, ROS1 or SETD2 | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | AL, AZ, CA, CO, FL, GA, ID, MD, MI, MN, MT, NH, NJ, NM, NY, OH, PA, TN, TX, VA, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Belvarafenib | HM95573 | BRAF kinase inhibitor | Clinical Trials | Camonsertib | RP-3500 | ATR kinase inhibitor | Clinical Trials | Divarasib | GDC-6036 | KRAS G12C inhibitor | Clinical Trials | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Pralsetinib | BLU-667 | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04625270 | II | Recurrent low grade serous ovarian cancer | A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | AZ, CA, CT, FL, IL, MD, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT04739618 | II | Advanced solid tumors - intratumoral injection | A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer | AZ | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Thermotherapy | | | Clinical Trials |
|
|
| NCT04771520 | II | Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I) | Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors | TX | View Drugs | |
Avapritinib | | PDGFRa and c-Kit inhibitor | Approved in Other Cancers |
|
|
| NCT04781088 | II | Platinum resistant ovarian cancer | Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer | OH, PA | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02896335 | II | Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A | A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway | MA | View Drugs | View Results |
Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04102436 | II | Advanced solid tumors | A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer | MD | View Drugs | |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Sleeping Beauty Transposed PBL | | Immune response against neoantigens | Clinical Trials |
|
|
| NCT04879121 | II | Advanced solid tumors with NTRK1-3 amplifications (at least 7 copies) | A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors | TX | View Drugs | View Results |
Larotrectinib | Trk inhibitor LOXO-101, LOXO-101, Vitrakvi | pan-Trk kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04919629 | II | Recurrent ovarian cancer with symptomatic ascites or pleural effusion | Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion | NY | View Drugs | |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Pegcetacoplan | C3-targeted complement inhibitor APL-2, APL-2 | Blocks the cleavage of C3 | Approved in Other Indications | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04931342 | II | Platinum resistant low-grade serous, low-grade endometrioid, clear cell, mucinous, undifferentiated, malignant Brenner tumors, small cell carcinoma of the ovary-hypercalcemic type or carcinosarcoma | A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | AZ, CA, MN, NC, OH, OK, OR, PA, TX, UT, VA, WA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Giredestrant | GDC-9545, selective estrogen receptor downregulator GDC-9545 | ER antagonist (SERD) | Clinical Trials | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04957615 | II | Advanced solid tumors with ARID1A mutations | A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors | TX | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04983745 | II | Advanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54L | A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer | TN | View Drugs | View Results |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05023655 | II | Advanced solid tumors with ARID1A mutations | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | SC | View Drugs | View Results |
Tazemetostat | histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438, Tazverik | EZH2 histone methyltransferase inhibitor | Approved in Other Cancers |
|
|
| NCT05064280 | II | Advanced solid tumors with brain metastases | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | TX | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05071937 | II | Recurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens) | Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05082025 | II | Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers |
|
|
| NCT05097599 | II | Advanced solid tumors with ALK or ROS1 fusions, BRAF V600X, BRCA1/2, or gPALB2 alterations, or HER2+, Nectin-4+ or TROP2+, or IRS-H+ or Angio TRS-H+ | Strata PATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors | DE, FL, OH, TN, WI | View Drugs | View Results |
Axitinib | Inlyta, AG-013736 | Multi-targeted RTK inhibitor | | Binimetinib | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi | MEK inhibitor | Approved in Other Cancers | Encorafenib | Raf Kinase Inhibitor LGX818, LGX818 | RAF inhibitor | Approved in Other Cancers | Enfortumab Vedotin | | ADC: anti-Nectin-4 + microtubule destabilizer (MMAE) | Approved in Other Cancers | Lorlatinib | PF-06463922 | ALK and ROS1 kinase inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Sacituzumab govitecan | Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132 | ADC: anti-TROP2 + topoisomerase I inhibitor (SN38) | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT05103358 | II | Advanced solid tumors with TSC1/2 alterations | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | AL, AZ, CA, CO, CT, FL, GA, HI, IN, LA, MD, MA, MI, MO, NE, NV, NJ, NY, NC, OH, OK, PA, SC, SD, TN, TX, UT, VA, WA, WI | View Drugs | View Results |
nab-Sirolimus | Nanoparticle Albumin-Bound Sirolimus, Nanoparticle Albumin-Bound Rapamycin, nab-rapamycin, ABI-009 | mTOR inhibitor | Approved in Other Cancers |
|
|
| NCT05113368 | II | Recurrect low grade serous ovarian cancer | Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial | OH | View Drugs | |
Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers |
|
|
| NCT05185947 | II | Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV) | Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05199584 | II | Advanced solid tumors with loss of function PTCH1 mutations | A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | CA, FL, IL, LA, NV, NY, NC, OH, PA, TN, TX, VA, WI | View Drugs | |
Taladegib | LY2940680, ENV-101 | Smoothened antagonist | Clinical Trials |
|
|
| NCT04992013 | II | Ovarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS) | Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS | MA | View Drugs | View Results |
|
|
| NCT05231122 | II | Recurrent serous, endometrioid or clear cell ovarian cancer | Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer | NY, TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | CDX-1140 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05262400 | II | Advanced solid tumors | A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | CA, MA, MI, MO, TX, WA | View Drugs | View Results |
PF-07104091 | | CDK2 inhibitor | Clinical Trials | PF-07220060 | | CDK4 inhibitor | Clinical Trials |
|
|
| NCT05272462 | II | Platinum resistant ovarian cancer | A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | IL | View Drugs | |
Minoxidil | | Kir6/SUR2 channel activator | Approved in Other Indications |
|
|
| NCT05286801 | II | Advanced solid tumors with loss of SMARCB1 or SMARCA1 | A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | AL, CA, CO, DC, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, PA, TN, TX, UT | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells | Clinical Trials |
|
|
| NCT05327010 | II | Advanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with PARP inhibitor therapy as immediate prior therapy or advanced solid tumors with a KRAS G12C mutation with prior KRAS G12C targeted therapy or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitor | Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET) | CA, CO, GA, IL, NC, PA, TX, VA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05337735 | II | Advanced solid tumors with dMMR or high MSI | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | TX | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT05453825 | II | Platinum resistant or refractory ovarian cancer | A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors | AR, CA, FL, GA, LA, NY, OH, TN | View Drugs | View Results |
Navicixizumab | OMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83 | DLL4 and VEGF antagonist | Clinical Trials |
|
|
| NCT05479045 | II | Platinum resistant or refractory ovarian cancer | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | DC, NJ | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | NY-ESO-1 Peptide vaccine | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials |
|
|
| NCT05489211 | II | Advanced solid tumors | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours | CA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WI | View Drugs | View Results |
AZD5305 | | PARP1 inhibitor | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Datopotamab deruxtecan | Anti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXd | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT05523440 | II | Recurrent ovarian cancer with ARID1A mutations | Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A) | OK | View Drugs | |
|
|
| NCT05538091 | II | Platinum resistant or refractory ovarian cancer | Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Vismodegib | Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 | Smoothened antagonist | Approved in Other Cancers |
|
|
| NCT05554328 | II | Recurrent or persistent ovarian cancer with alterations in BRAF, HRAS, KRAS, NRAS, MEK1/2 or NF1 | A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial | AL, AZ, CA, FL, ID, IL, IA, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, ND, OH, OK, OR, PA, RI, SD, TX, WA, WV, WI | View Drugs | View Results |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Selumetinib | ARRY-142886, AZD6244, Koselugo | MEK1/2 inhibitor | Approved in Other Cancers |
|
|
| NCT05554380 | II | Advanced solid tumors with an activating AKT mutation | Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial | AL, AZ, CA, FL, ID, IL, IA, ME, MD, MI, MN, MT, NV, NY, ND, OH, OK, OR, PA, SD, TX, WA, WI | View Drugs | View Results |
Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05503797 | II | Advanced solid cancers with a BRAF fusion | A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations | CA, FL, MD, MO, NE, OH | View Drugs | |
Plixorafenib | 8394, BRAF inhibitor PLX8394, FORE8394 | BRAF kinase inhibitor | Clinical Trials |
|
|
| NCT05661578 | II | Advanced PD-L1+ solid tumors | A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors | NE, WA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells | Clinical Trials |
|
|
| NCT05673928 | II | Advanced HER2+ solid tumors with brain metastases | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | TX | View Drugs | |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT05142241 | II | Recurrent rare tumors | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide | MD | View Drugs | |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT05700721 | II | Advanced solid tumors with active brain metastases and with alterations in ATM, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51, RAD51B/C/D, RAD52, or RAD54L | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | TX | View Drugs | |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05733000 | II | Advanced solid tumors | Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers | IL | View Drugs | |
Devimistat | CPI-613, alpha-lipoic acid analogue CPI-613 | Undisclosed mechanism | Clinical Trials | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Hydroxychloroquine | Plaquenil | Autophagy inhibitor | |
|
|
| NCT05798611 | II | Advanced solid tumors with dMMR or high MSI | A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST) | MA, NY, OK, PA, RI | View Drugs | |
ART0380 | | ATR kinase inhibitor | Clinical Trials |
|
|
| NCT06003231 | II | Platinum resistant HER2+ ovarian cancer | A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2 | CA, CT, MI, MT, NY, OH, TX | View Drugs | |
Disitamab vedotin | anti-HER2 ADC RC48, RC48-ADC | ADC: anti-HER2 + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT04332653 | Ib/IIa | Advanced solid tumors (Phase II) | An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors | FL, MI, MO, NC, PA, TN, TX | View Drugs | View Results |
Efineptakin alfa | NT-I7, GX-I7, Hyleukin, recombinant human IL-7-hybrid Fc NT-I7, TJ107 | IL-7R agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05700669 | Ib/II | Recurrent ovarian cancer | A Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid Tumors | TX | View Drugs | |
AsiDNA | DNA repair inhibiting oligonucleotide | DNA Repair decoy | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03872947 | Ib | Recurrent ovarian cancer | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, LA, NJ, NY, OR, TX, VA, WI | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|
| NCT03842228 | Ib | Advanced solid tumors with alterations in BARD1, BRCA1/2, BRIP1, FANCA, NBN, PALB2, PIK3CA (E542, E545 or H1047), PTEN, RAD51, RAD51B/C/D (in expansion) | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors | CA, CO, IL, MA, OH, PA, TX, WI | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04130516 | I/IIa | Advanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II) | A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab | CA, CT, MA, NM, NY, PA, TX | View Drugs | View Results |
LNS8801 | G protein-coupled estrogen receptor agonist LNS8801 | GPER agonist | Clinical Trials |
|
|
| NCT04553133 | I/IIa | Platinum resistant ovarian cancer (Phase II) | PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | IA, KY, MA, MI, NJ, NY, TX, VA | View Drugs | View Results |
PF-07104091 | | CDK2 inhibitor | Clinical Trials |
|
|
| NCT04657068 | I/IIa | Platinum resistant high grade serous ovarian cancer (at most 1 prior therapy for platinum resistant disease) or advanced solid tumors with an ATM alteration (Phase II) | A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors | AL, AR, CO, FL, OK, PA, TN, TX | View Drugs | View Results |
ART0380 | | ATR kinase inhibitor | Clinical Trials | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer (Phase II) | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02068794 | I/II | Platinum resistant or refractory ovarian cancer (Phase II) | Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer | MN | View Drugs | |
MV-NIS infected mesynchymal stem cells | | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03287271 | I/II | Platinum resistant or persistent ovarian cancer | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | CA | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03564340 | I/II | Platinum resistant or refractory ovarian cancer (Phase II) | A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer | AL, MA, MN, NY, OH, OK, TN | View Drugs | View Results |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Ubamatamab | REGN4018, anti-MUC16/CD3 bispecific antibody REGN4018 | Re-directs T cells to attack MUC16 (CA125)+ tumor cells | Clinical Trials |
|
|
| NCT03157128 | I/II | Advanced solid tumors with RET alterations (Phase II) | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
Selpercatinib | LOXO-292, RET kinase inhibitor LOXO-292, Retevmo | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03767348 | I/II | Advanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II) | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | AZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WA | View Drugs | View Results |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | RP1 | oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03907852 | I/II | Advanced mesothelin+ solid tumors (Phase II) | A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer | CA, FL, IL, MD, NY, NC, PA, TN, TX | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Gavocabtagene autoleucel | TC-210 T cells, TC-210 TruC-T cells, autologous anti-mesothelin T-cell receptor fusion construct T cells TC-210 | Immune response against cancer expressing mesothelin | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03919292 | I/II | Advanced solid tumors with RAS mutations (Phase II) | Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers | VA | View Drugs | View Results |
Neratinib | HKI-272, PD272 | EGFR, HER2, HER4 kinase inhibitor | Approved in Other Cancers | Valproic acid | Depacon, Depakene, Stavzor, Valproate | HDAC and NOS inhibitor | Approved in Other Indications |
|
|
| NCT04143711 | I/II | Advanced solid tumors with ERBB2 AMP (Phase II) | A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications | CA, KS, LA, MD, NY, OH, PA, RI, TN, TX, WA, WI | View Drugs< |